Instrumentation. Chromatographic separations were carried out on an Agilent 1100 series chromatographic system (Agilent Technologies, Palo Alto, CA, USA) using a SHISEIDO C18 column (2.0 I.D. × 150 mm in length) for the separation of synthetic chemicals, and a Zorbax 300SB C18 column (1.0 I.D. × 50 mm in length; particle size, 3.5 µm) for the separation of proteins. The gradient elution program for both columns was as follows: The 95% mobile phase A (0.05% TFA in UPW) was maintained for 5 min, then mobile phase B (0.05% TFA in ACN) was increased from 5 to 80% in 45 min with a flow rate of 0.05 mL min -1 . ESI-MS experiments were performed in positive mode on an Esquire-LC ESI ion trap mass spectrometer (Bruker Daltonics, Bremen, Germany) . The operational parameters were as follows: nebulizer, 65 psi; dry gas, 8 L min -1 ; dry temperature, 300 °C; capillary voltage, -3500 V; endplate offset, -500 V. Inductively coupled plasma mass spectrometry (ICPMS) experiments were performed on an ELAN DRC II ICPMS (PerkinElmer, SCIEX, Canada) equipped with a concentric pneumatic nebulizer and a cyclonic spray chamber. The ICPMS operational parameters were as follows: nebulizer gas, 0.88 L min -1 ; auxiliary gas, 1.0 L min -1 ; plasma gas, 15 L min -1 ; RF power, 1200 W; dwell time, 100 ms; lens voltage, 7.2 V. Parameters such as nebulizer gas flow and lens voltage were optimized daily to obtain the best sensitivity. 2 H-and 13 C-NMR spectra were collected on a Bruker AV-400 (400 MHz) spectrometer. Chemical shifts are given in ppm (δ) relative to tetramethylsilane as an internal standard. Figure S3 ): δ 171. 90, 171.73, 153.87, 146.71, 143.03, 139.87, 139.35, 138.44, 137.88, 129.40, 127.76, 121.85, 120.49, 110.22, 109.55, 108.78, 68.73, 64.37, 56.52, 38.70, 38.30, 32.09, 27.59, 26.97, 26.68, 25.65, 25.43, 25.18, 20.69 . 154.27, 150.85, 147.87, 144.27, 141.15, 139.98, 130.12, 127.66, 127.09, 125.15, 119.97, 108.87, 108.17, 76.06, 68.55, 65.82, 56.23, 47.20, 40.14, 38.63, 26.90, 26.39, 25.27, 24.83, 20 .61. 
Synthesis of N-Boc-6-azido-L-norleucine-N-Fmoc-1,4-butanediamine Derivative (Compound 7).
(N-Boc-6-azido-Lnorleucine)(dicyclohexylammonium) salt (180 mg) was dissolved in 5 mL of ACN, and then 152 mg of HATU and 0.8 mL of DIPEA were added to activate the carboxyl group for 10 min. N-Fmoc-1,4-butanediamine (156 mg) was then added into the mixture at 0 o C. The mixture was stirred at room temperature for 3 h. The resulting product was further purified using silica chromatography (Ethyl Acetate: Petroleum Either = 7:3) ( Figure S7a ) and confirmed using ESI-MS m/z: 565.2 ( Figure S7b 27, 156.55, 155.73, 144.40, 141.20, 128.05, 127.51, 125.60, 120.57, 78.40, 65.64, 54.53, 51.02, 47.25, 38.62, 32.12, 28.64, 28.37, 27.21, 26.83, 23.19 . 
Synthesis of amine-DOTA-Azide (Compound 10). Boc protection of Compound 7 was removed in TFA to give compound 8
with an m/z of 465.0. Then compound 8 (46.4 mg) was mixed with DOTA-NHS in 2 mL of MeOH/ACN (1/1), and then 100 μL of DIPEA were added. The mixture was stirred at room temperature overnight. 4-methylpiperidine (0.5 mL) was finally added to remove the Fmoc protection. The resulting product was further purified using HPLC ( Figure S10a ) and confirmed using ESI-MS m/z: 565.2 ( Figure S10b) ; 1 H NMR (CD 3 CN) ( Figure S11 ) and 13 C NMR (CD 3 CN) δ ppm ( Figure S12 ): δ 160. 46, 160.12, 118.38, 115.46, 54.16, 50.92, 48.56, 48.35, 48.14, 47.92, 47.71, 47.50, 47.29, 42.33, 30.80, 28.10, 22.88, 17.58, 16.31, 11.62, 9.42, 8.77 . Figure S15 ): δ 171. 72, 170.92, 156.56, 155.63, 154.03, 147.24, 144.40, 141.19, 139.74, 133.84, 128.05, 127.50, 125.60, 120.56, 108.93, 68.84, 67.47, 65.62, 56.63, 53.33, 51.14, 50.97, 47.24, 38.68, 32.38, 32.05, 28.35, 27.34, 26.93, 26.72, 25.18, 22.94, 22.33 . in 2 mL MeOH/DMSO (3:1), then 0.5 mL of DIPEA was added. The mixture was shaken at room temperature for 3 h.
Compound 12 was purified with HPLC and confirmed using ESI-MS m/z: 1498 ( Figure S17a ). 0.2 mL of Compound 12 (18 mM) was mixed with 0.4 mL of Eu(NO 3 ) 3 solution (10 mM in 2 % HNO 3 ), 2 mL of 100 mM MES buffer (pH = 6.0) and 1 mL ACN. Compound 12-Eu was confirmed using ESI-MS m/z: 1646 ( Figure S17b ). To synthesize Biotin-PEG-Nitrobenzyl-DOTA-Eu-SF (Compound 14), 1.44 mL of compound 12-Eu (1 mM) was mixed with 136 μL of compound 13 (40 mM in DMSO, synthesized as described in Figure S18 ), 42 μL TBTA (20 mM in t-butanol), 168 μL CuSO 4 (50 mM in 100 mM, pH = 7.5 Tris-HCl) and 282 μL ascorbate (150 mM in H 2 O) in 1.68 mL of 100 mM Tris-HCl (pH = 9.0) with 1.2 mL t-butanol for 1h at room temperature. The pH value of the reaction was adjusted to 6.0 with TFA to prevent the hydrolysis of the sulfonyl fluoride group in compound 14. The final product of compound 14 was purified using HPLC (Figure 2a 
